1. Home
  2. IMPP vs MGNX Comparison

IMPP vs MGNX Comparison

Compare IMPP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imperial Petroleum Inc.

IMPP

Imperial Petroleum Inc.

HOLD

Current Price

$4.98

Market Cap

234.7M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.31

Market Cap

262.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMPP
MGNX
Founded
1981
2000
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.7M
262.4M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
IMPP
MGNX
Price
$4.98
$3.31
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $8.00
AVG Volume (30 Days)
438.3K
★ 544.4K
Earning Date
09-10-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $149,500,000.00
Revenue This Year
$86.14
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.68
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.15
$1.29
52 Week High
$6.57
$5.08

Technical Indicators

Market Signals
Indicator
IMPP
MGNX
Relative Strength Index (RSI) 41.56 36.53
Support Level $4.83 $2.78
Resistance Level $5.00 $3.39
Average True Range (ATR) 0.20 0.23
MACD -0.04 -0.03
Stochastic Oscillator 24.39 13.33

Price Performance

Historical Comparison
IMPP
MGNX

About IMPP Imperial Petroleum Inc.

Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: